All Scientific Advisory Board members are RHI Shareholders


Dr. Staecker is the Principal Investigator for the first gene therapy trial (CGF166) to restore hearing in patients with severe-to-profound hearing loss.  Dr. Staecker’s clinical practice is focused on Neurotology, and Otology. Dr. Staecker is also the Principal Investigator for the Kansas City investigative site for a Phase 2b Study of SPI-1005 to reduce the Incidence, Severity, and Duration of Acute Noise Induced Hearing Loss (NIHL).  Dr. Staecker’s research focuses on developing treatments for hearing loss. Currently, the main effort of his research lab is focused on developing gene therapy for the treatment of an inner ear disease. Dr. Staecker is also involved in clinical studies on cochlear implants and a totally implanted hearing aid.  Dr. Staecker has published numerous articles and book chapters and is the Director Division of Otology/Neurotology-Dept of Otolaryngology- Head and Neck Surgery; Tenured Professor, Dept of Otolaryngology- Head and Neck Surgery; Tenured Professor, Dept of Hearing and Speech; Tenured Professor, Dept of Neurosurgery.


Dr. Chen’s research interests include functional genomics of hearing, inner ear hair cell regeneration, mechanisms and treatment for age-related and noise-induced hearing loss (ARHL and NIHL) and gene therapy for hereditary deafness.


Xue Zhong Liu, M.D., Ph.D., FACS., an internationally renowned surgeon-scientist, is the Leonard M. Miller Professor and Vice Chair of Otolaryngology and Professor of Human Genetics, Biochemistry and Pediatrics. Dr. Liu is also Vice Chair of Research in the Department of Otolaryngology at the University of Miami Miller School of Medicine. Dr. Liu is Director ofthe Miami Otogenic Program and the Director of the Center for Communication Sciences & Disorders.


Hernandez is a well-respected and proven entrepreneurial leader with extensive experience in company creation, early-stage technology development, with private and public market financing. He has founded or led six entrepreneurial companies in cutting-edge arenas, raising over $150M in investment capital and commercialized respective products. Hernandez has launched and played key roles in paradigm-shifting-technologies such as COX-2 inhibitors, microarrays, Human Papillomavirus (HPV) diagnostics, biological sensors, personalized medicine, and oncology. He possesses a broad knowledge of licensing, operations, marketing, financing, and deal structuring. He is an executive with a strong educational background in biology, medicine, molecular genetics, microbiology, epidemiology, marketing, and finance. Hernandez is an excellent communicator and presenter, with extensive world travels and experience in managing and interacting with diverse cultures, high-level executives and elected officials.


Dr. Holt received his Ph.D. from the Department of Physiology at the University of Rochester in 1995. He then completed a postdoctoral fellowship with the Howard Hughes Medical Institute at Harvard Medical School, under the direction of David Corey. In 2001, Dr. Holt accepted a position working in the Neuroscience department at the University of Virginia. In 2011, Dr. Holt returned to Harvard to join the Department of Otolaryngology, the F.M. Kirby Neurobiology Center and the Neurobiology Program at Boston Children’s Hospital. In 2016, Dr. Holt became a professor of Otolaryngology and Neurology at Harvard Medical School. Currently, he also carries out research for the F.M Kirby Neurobiology Center and the Neurobiology program at Boston Children’s Hospital.